Erlotinib Hydrochloride

ERLOTINIB HYDROCHLORIDE- erlotinib tablet, film coated
Mylan Institutional Inc.

1 INDICATIONS AND USAGE

1.1 Non-Small Cell Lung Cancer (NSCLC)

Erlotinib tablets are indicated for:

  • The treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen [see Clinical Studies (14.1, 14.3)] .

Limitations of Use

  • Safety and efficacy of erlotinib tablets have not been established in patients with NSCLC whose tumors have other EGFR mutations [see Clinical Studies (14.1, 14.2)] .
  • Erlotinib tablets are not recommended for use in combination with platinum-based chemotherapy [see Clinical Studies (14.4)] .

1.2 Pancreatic Cancer

Erlotinib tablets in combination with gemcitabine is indicated for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer [see Clinical Studies (14.5)] .

2 DOSAGE AND ADMINISTRATION

2.1 Selection of Patients with Metastatic NSCLC

Select patients for the treatment of metastatic NSCLC with erlotinib tablets based on the presence of EGFR exon 19 deletions or exon 21 (L858R) substitution mutations in tumor or plasma specimens [see Clinical Studies (14.1, 14.2)] . If these mutations are not detected in a plasma specimen, test tumor tissue if available. Information on FDA-approved tests for the detection of EGFR mutations in NSCLC is available at: http://www.fda.gov/CompanionDiagnostics.

2.2 Recommended Dose – NSCLC

The recommended daily dose of erlotinib tablets for NSCLC is 150 mg taken on an empty stomach, i.e., at least one hour before or two hours after the ingestion of food. Treatment should continue until disease progression or unacceptable toxicity occurs.

2.3 Recommended Dose – Pancreatic Cancer

The recommended daily dose of erlotinib tablets for pancreatic cancer is 100 mg taken once daily in combination with gemcitabine. Take erlotinib tablets on an empty stomach, i.e., at least one hour before or two hours after the ingestion of food. Treatment should continue until disease progression or unacceptable toxicity occurs [see Clinical Studies (14.5)] .

2.4 Dose Modifications

*
For additional information see Warnings and Precautions (5).
Reduce erlotinib tablets by 50 mg decrements when restarting therapy following withholding treatment for a dose-limiting toxicity that has resolved to baseline or grade ≤ 1.
For additional information see Drug Interactions (7).
§
For additional information see Clinical Pharmacology (12.3).

Adverse Reactions

Pulmonary *

Interstitial Lung Disease (ILD)

Discontinue erlotinib tablets

During diagnostic evaluation for possible ILD

Withhold erlotinib tablets

Hepatic *

Severe hepatic toxicity that does not improve significantly or resolve within three weeks

Discontinue erlotinib tablets

In patients with pre-existing hepatic impairment or biliary obstruction for doubling of bilirubin or tripling of transaminases values over baseline

Withhold erlotinib tablets * and consider discontinuation

In patients without pre-existing hepatic impairment for total bilirubin levels greater than 3 times the upper limit of normal or transaminases greater than 5 times the upper limit of normal

Withhold erlotinib tablets and consider discontinuation

Renal *

For severe (CTCAE grade 3 to 4) renal toxicity

Withhold erlotinib tablets and consider discontinuation

Gastrointestinal *

Gastrointestinal perforation

Discontinue erlotinib tablets

For persistent severe diarrhea not responsive to medical management (e.g., loperamide)

Withhold erlotinib tablets

Skin *

Severe bullous, blistering or exfoliating skin conditions

Discontinue erlotinib tablets

For severe rash not responsive to medical management

Withhold erlotinib tablets

Ocular *

Corneal perforation or severe ulceration

Discontinue erlotinib tablets

For keratitis of (NCI-CTC version 4.0) grade 3-4 or for grade 2 lasting more than 2 weeks

Withhold erlotinib tablets

For acute/worsening ocular disorders such as eye pain

Withhold erlotinib tablets and consider discontinuation

Drug Interactions

CYP3A4 inhibitors

If severe reactions occur with concomitant use of strong CYP3A4 inhibitors [such as atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), voriconazole, or grapefruit or grapefruit juice] or when using concomitantly with an inhibitor of both CYP3A4 and CYP1A2 (e.g., ciprofloxacin)

Reduce erlotinib tablets by 50 mg decrements; avoid concomitant use if possible

CYP3A4 inducers

Concomitant use with CYP3A4 inducers, such as rifampin, rifabutin, rifapentine, phenytoin, carbamazepine, phenobarbital, or St. John’s Wort

Increase erlotinib tablets by 50 mg increments at 2-week intervals to a maximum of 450 mg as tolerated. Avoid concomitant use if possible

Concurrent Cigarette Smoking §

Concurrent cigarette smoking

Increase erlotinib tablets by 50 mg increments at 2-week intervals to a maximum of 300 mg. Immediately reduce the dose of erlotinib tablets to the recommended dose (150 mg or 100 mg daily) upon cessation of smoking

Proton Pump inhibitors

Separation of doses may not eliminate the interaction since proton pump inhibitors affect the pH of the upper GI tract for an extended period

Avoid concomitant use if possible

H 2 -receptor antagonists

If treatment with an H 2 -receptor antagonist such as ranitidine is required, separate dosing.

Erlotinib tablets must be taken 10 hours after the H 2 -receptor antagonist dosing and at least 2 hours before the next dose of the H 2 -receptor antagonist

Antacids

The effect of antacids on erlotinib pharmacokinetics has not been evaluated.

The antacid dose and the erlotinib tablets dose should be separated by several hours, if an antacid is necessary

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2020. All Rights Reserved.